J&J’s Imaavy Scores Pivotal Win in Rare Blood Disorder, Eyes First-Ever wAIHA Approval
Rare Disease & Gene Therapy — June 11, 2026
Pivotal readouts dominated this edition, led by J&J’s win for Imaavy in a rare blood disorder with no approved therapy, alongside fresh pipeline data from Novartis in muscular dystrophy and Vertex’s pediatric CASGEVY results at EHA.
Top developments in this edition:
- J&J’s Imaavy (nipocalimab) posted a pivotal Phase 2/3 win in warm autoimmune hemolytic anemia (wAIHA), a rare condition with no approved treatment, setting up a filing that could make it the first therapy for the indication (Pharmaphorum; Fierce Pharma)
- Novartis presented updated Phase 2 data for its DUX4-silencing RNA medicine in facioscapulohumeral muscular dystrophy (FSHD), the asset from its $12 billion Avidity Biosciences acquisition, in a space with no approved disease-modifying therapy (MedCity News)
- Vertex disclosed CASGEVY data in children ages 5 to 11 with sickle cell disease and transfusion-dependent beta thalassemia at the EHA Congress and expanded global regulatory submissions (Vertex Pharmaceuticals)
- An expanded-access protocol for a lentiviral shmiR fetal-hemoglobin gene therapy in sickle cell disease was listed as temporarily unavailable on ClinicalTrials.gov, with no public explanation disclosed (ClinicalTrials.gov)
What to Watch
- Imaavy wAIHA filing & label — The regulatory submission timeline and label language around prior-therapy eligibility will be key variables for payer contracting across the estimated 15,000–30,000 US wAIHA patients.
- Novartis FSHD next step — A Phase 3 initiation announcement would test the $12 billion Avidity acquisition thesis; DUX4 genetic-testing access is an early commercial-readiness indicator for this genetically targeted RNA program.
- CASGEVY pediatric expansion — Vertex’s submissions across multiple geographies set up a series of label-expansion decisions through 2026–2027 that will shape addressable market size and national-payer pricing.
- Lentiviral access pause — The temporarily unavailable shmiR fetal-hemoglobin expanded-access protocol warrants monitoring for disclosure of the underlying cause, with potential read-through to investigator-sponsored sickle cell gene therapy programs.
This brief highlights the edition’s top stories. Read the full edition → for all stories, source links, competitive landscape, and analysis — or browse the Rare Disease & Gene Therapy archive.
